Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Due to unavailability of the drug.

Conditions

Type 1 Hyperlipoproteinemia

Interventions

DRUG: SLx-4090 placebo
DRUG: Orlistat Placebo
DRUG: Orlistat
DRUG: Slx-4090

Sponsor

University of Texas Southwestern Medical Center